Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 16/20 | 0.58 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2792109 | 0.86 | PHGDH (0.61) | PHGDHPIN1 | |
| SCHEMBL28014535 | 0.85 | MAPT (0.52) | PHGDHPOLBMAPT | |
| SCHEMBL13078329 | 0.85 | PHGDH (0.59) | PHGDHPIN1 | |
| SCHEMBL12278253 | 0.84 | CYP2A6 (0.48) | PHGDHMAPT | |
| SCHEMBL28013863 | 0.84 | MEN1 (0.47) | PHGDHMAPT | |
| SCHEMBL28014536 | 0.84 | HDAC3 (0.55) | PHGDHMAPT | |
| SCHEMBL2678185 | 0.83 | PHGDH (0.60) | PHGDHPIN1 | |
| SCHEMBL4298598 | 0.81 | PHGDH (0.59) | PHGDHPIN1 | |
| SCHEMBL13028743 | 0.81 | PHGDH (0.56) | PHGDHPIN1MAPT | |
| SCHEMBL13044184 | 0.81 | PHGDH (0.63) | PHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210380537-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2021-12-09 | — | — | US | disclosed |
| US-20200048205-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2020-02-13 | — | — | US | disclosed |
| US-10351531-B2 | Pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20170320831-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2017-11-09 | — | — | US | disclosed |
| US-9732039-B2 | Pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | Arena Pharmeceuticals, Inc. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9434692-B2 | Pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160075660-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2016-03-17 | — | — | US | disclosed |
| CN-102838546-B | Pyrazole derivatives as modulators of 5-ht2a serotonin receptor useful for treatment of disorders related thereto | ARENA PHARM INC | 2015-07-15 | — | — | CN | disclosed |
| EP-2066641-B1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2014-06-04 | — | — | EP | disclosed |
| US-20130217700-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| CN-102838546-A | Pyrazole derivatives as modulators of 5-ht2a serotonin receptor useful for treatment of disorders related thereto | ARENA PHARM INC | 2012-12-26 | — | — | CN | disclosed |
| CN-101611013-B | As 5-HT2APyrazole derivatives of serotonin receptor modulators for the treatment of disorders related thereto | ARENA PHARM INC | 2012-09-05 | — | — | CN | disclosed |
| US-20100286092-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL, LTD. (BM) | 2010-11-11 | — | — | US | disclosed |
| EP-2220097-A1 | BETA-LACTAMASE INHIBITORS | Protez Pharmaceuticals, Inc. (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2010056827-A1 | BETA-LACTAMASE INHIBITORS | PROTEZ PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100120715-A1 | BETA-LACTAMASE INHIBITORS | PROTEZ PHARMACEUTICALS, INC. | 2010-05-13 | — | — | US | disclosed |
| US-20100004264-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2010-01-07 | — | — | US | disclosed |
| CN-101611013-A | As 5-HT2APyrazole derivatives of serotonin receptor modulators for the treatment of disorders related thereto | ARENA PHARM INC (US) | 2009-12-23 | — | — | CN | disclosed |
| WO-2009064414-A1 | BETA-LACTAMASE INHIBITORS | PROTEZ PHARMACEUTICALS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004264-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR2B | PHGDH 4105/4885PIN1 2565/4885POLB 4428/4885 |
| US-20200048205-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR2C | PHGDH 4195/4885PIN1 2635/4885POLB 4505/4885 |
| US-20100120715-A1 | BETA-LACTAMASE INHIBITORS | GANAB, BPGM, BLVRB | PHGDH 193/4885PIN1 3134/4885POLB 293/4885 |
| US-20130217700-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR2A, HTR5A, HTR2C | PHGDH 4181/4885PIN1 2162/4885POLB 4458/4885 |
| US-20210380537-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR2B | PHGDH 4105/4885PIN1 2565/4885POLB 4428/4885 |
| US-20170320831-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR3A | PHGDH 4118/4885PIN1 2614/4885POLB 4498/4885 |
| US-10351531-B2 | Pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | HTR5A, HTR2A, HTR3A | PHGDH 4118/4885PIN1 2614/4885POLB 4498/4885 |
| US-20100286092-A1 | BETA-LACTAMASE INHIBITORS | GANAB, BPGM, BLVRB | PHGDH 193/4885PIN1 3134/4885POLB 293/4885 |
| US-20160075660-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR2B | PHGDH 4105/4885PIN1 2565/4885POLB 4428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.